Systemic administration of IL-10 could not improve IBD symptoms or prevent reoccurence of the disease (16–18), while subcutaneous injections of IL-10, below the psoriatic plaques, could decrease the dermal lymphocyte infiltrates and ameliorate the clinical symptoms (19–22). This evidence concerns the gene IL10 and inflammatory bowel disease.